Alpha-mannosidosis

Dag Malm, Øivind Nilssen, Dag Malm, Øivind Nilssen

Abstract

Alpha-mannosidosis is an inherited lysosomal storage disorder characterized by immune deficiency, facial and skeletal abnormalities, hearing impairment, and intellectual disability. It occurs in approximately 1 of 500,000 live births. The children are often born apparently normal, and their condition worsens progressively. Some children are born with ankle equinus or develop hydrocephalus in the first year of life. Main features are immune deficiency (manifested by recurrent infections, especially in the first decade of life), skeletal abnormalities (mild-to-moderate dysostosis multiplex, scoliosis and deformation of the sternum), hearing impairment (moderate-to-severe sensorineural hearing loss), gradual impairment of mental functions and speech, and often, periods of psychosis. Associated motor function disturbances include muscular weakness, joint abnormalities and ataxia. The facial trait include large head with prominent forehead, rounded eyebrows, flattened nasal bridge, macroglossia, widely spaced teeth, and prognathism. Slight strabismus is common. The clinical variability is significant, representing a continuum in severity. The disorder is caused by lysosomal alpha-mannosidase deficiency. Alpha-mannosidosis is inherited in an autosomal recessive fashion and is caused by mutations in the MAN2B1 gene located on chromosome 19 (19 p13.2-q12). Diagnosis is made by measuring acid alpha-mannosidase activity in leukocytes or other nucleated cells and can be confirmed by genetic testing. Elevated urinary secretion of mannose-rich oligosaccharides is suggestive, but not diagnostic. Differential diagnoses are mainly the other lysosomal storage diseases like the mucopolysaccharidoses. Genetic counseling should be given to explain the nature of the disease and to detect carriers. Antenatal diagnosis is possible, based on both biochemical and genetic methods. The management should be pro-active, preventing complications and treating manifestations. Infections must be treated frequently. Otolaryngological treatment of fluid in the middle ear is often required and use of hearing aids is invariably required. Early educational intervention for development of social skills is needed and physiotherapy is important to improve bodily function. Orthopedic surgery may be necessary. The long-term prognosis is poor. There is an insidiously slow progression of neuromuscular and skeletal deterioration over several decades, making most patients wheel-chair dependent. No patients manage to be completely socially independent. Many patients are over 50 years of age.

Figures

Figure 1
Figure 1
Facial features in alpha-mannosidosis. A. Twins aged 18 Months. Note enlarged head, short neck, rounded eyebrows, saddle nose, and prominent forehead. B. Same twins aged 8 years. Note slight muscular atrophy of the hands. C. Boy, aged 27. Note: Hearing aid.
Figure 2
Figure 2
Radiography of kyphoscoliosis in alpha-mannosidosis before and after orthopedic correction. A. Kyphoscoliosis with skeletal abnormalities of all vertebrae. B. Orthopedic correction of kyphosis.
Figure 3
Figure 3
Coxarthrosis in alpha-mannosidosis. A. Coxarthrosis at 8 years of age. B. Progression of coxarthrosis at age 13.
Figure 4
Figure 4
Electron micrograph of a vacuolated lymphocyte. Electron micrograph of a vacuolated lymphocyte from a mannosidosis patient (A) as compared to a lymphocyte from a normal control (B).
Figure 5
Figure 5
The 3-dimensional structure of lysosomal α-mannosidase. Peptides are coloured a-red, b-orange, c-yellow, d-green and e-blue. The active site is denoted by a Zn++ ion. Two mutant sites are displayed, demonstrating the effect of mutations c.215A>T: p.H72L affecting Zn++ coordination in the actives site (group 1 mutation, see text for explanation) and the prevalent mutation c.2248C>T: p.R750W which is likely affecting peptide e-d interaction (group 2 mutation, see text for explanation). The figure was kindly provided by Dr. P. Heikinheimo, University of Helsinki, Finland. It has been prepared with the program PyMol [72].

References

    1. Ockerman PA. A generalised storage disorder resembling Hurler's syndrome. Lancet. 1967;2:239. doi: 10.1016/S0140-6736(67)92303-3.
    1. Ockerman PA. Mannosidosis: isolation of oligosaccharide storage material from brain. J Pediatr. 1969;75:360–365. doi: 10.1016/S0022-3476(69)80259-3.
    1. Loeb H, Vamos-Hurwitz E. Mannosidosis. Arch Neurol. 1977;34:650–651.
    1. Bach G, Kohn G, Lasch EE, El Massri M, Ornoy A, Sekeles E, Legum C, Cohen MM. A new variant of mannosidosis with increased residual enzymatic activity and mild clinical manifestation. Pediatr Res. 1978;12:1010–1015. doi: 10.1203/00006450-197810000-00012.
    1. Heikinheimo P, Helland R, Leiros HK, Leiros I, Karlsen S, Evjen G, Ravelli R, Schoehn G, Ruigrok R, Tollersrud OK, McSweeney S, Hough E. The structure of bovine lysosomal alpha-mannosidase suggests a novel mechanism for low-pH activation. J Mol Biol. 2003;327:631–644. doi: 10.1016/S0022-2836(03)00172-4.
    1. Jolly RD, Water NS Van de, Janmaat A, Slack PM, McKenzie RG. Zinc therapy in the bovine mannosidosis model. Birth Defects Orig Artic Ser. 1980;16:305–318.
    1. Wong LT, Vallance H, Savage A, Davidson AG, Applegarth D. Oral zinc therapy in the treatment of alpha-mannosidosis. Am J Med Genet. 1993;46:410–414. doi: 10.1002/ajmg.1320460413.
    1. HUE-MAN Towards the Development of an Effective Enzyme Replacement Therapy for Human á-Mannosidosis. 2006.
    1. Desnick RJ, Sharp HL, Grabowski GA, Brunning RD, Quie PG, Sung JH, Gorlin RJ, Ikonne JU. Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediatr Res. 1976;10:985–996. doi: 10.1203/00006450-197612000-00008.
    1. Autio S, Louhimo T, Helenius M. The clinical course of mannosidosis. Ann Clin Res. 1982;14:93–97.
    1. Olmez A, Nilssen O, Coskun T, Klenow H. Alpha-mannosidosis and mutational analysis in a Turkish patient. Turk J Pediatr. 2003;45:46–50.
    1. Gutschalk A, Harting I, Cantz M, Springer C, Rohrschneider K, Meinck HM. Adult alpha-mannosidosis: clinical progression in the absence of demyelination. Neurology. 2004;63:1744–1746.
    1. Urushihara M, Kagami S, Yasutomo K, Ito M, Kondo S, Kitamura A, Malm D, Klenow H, Nilssen O, Kuroda Y. Sisters with alpha-mannosidosis and systemic lupus erythematosus. Eur J Pediatr. 2004;163:192–195. doi: 10.1007/s00431-004-1404-2.
    1. Chester MA, Lundblad A, Öckerman PA, Autio S. Mannosidosis. In: Duran P, O'Brien JF, editor. Genetic Errors of Glyco-Protein Metabolism. Milan: Edi-Hermes; 1982. pp. 89–120.
    1. Berg T, Riise HM, Hansen GM, Malm D, Tranebjaerg L, Tollersrud OK, Nilssen O. Spectrum of mutations in alpha-mannosidosis. Am J Hum Genet. 1999;64:77–88. doi: 10.1086/302183.
    1. Malm D, Nilssen O. Alpha-Mannosidosis. GeneReviews. Medical Genetics Information Resource [Database online] 2006.
    1. Malm D, Tollersrud OK, Tranebjaerg L, Mansson JE. [Alpha-mannosidosis] Tidsskr Nor Laegeforen. 1995;115:594–597.
    1. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114:909–916. doi: 10.1542/peds.2004-0583.
    1. Aylsworth AS, Taylor HA, Stuart CM, Thomas GH. Mannosidosis: phenotype of a severely affected child and characterization of alpha-mannosidase activity in cultured fibroblasts from the patient and his parents. J Pediatr. 1976;88:814–818. doi: 10.1016/S0022-3476(76)81120-1.
    1. Halperin JJ, Landis DM, Weinstein LA, Lott IT, Kolodny EH. Communicating hydrocephalus and lysosomal inclusions in mannosidosis. Arch Neurol. 1984;41:777–779.
    1. Crawley AC, Walkley SU. Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis. J Neuropathol Exp Neurol. 2007;66:687–697. doi: 10.1097/nen.0b013e31812503b6.
    1. de Jong G, Petersen EM. First reported case of alpha-mannosidosis in the RSA. S Afr Med J. 1992;82:126–128.
    1. Odunusi E, Peters C, Krivit W, Ogilvie J. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop. 1999;19:270–274. doi: 10.1097/00004694-199903000-00026.
    1. Eckhoff DG, Garlock JS. Severe destructive polyarthropathy in association with a metabolic storage disease. A case report. J Bone Joint Surg Am. 1992;74:1257–1261.
    1. DeFriend DE, Brown AE, Hutton CW, Hughes PM. Mannosidosis: an unusual cause of a deforming arthropathy. Skeletal Radiol. 2000;29:358–361. doi: 10.1007/s002560000213.
    1. Gerards AH, Winia WP, Westerga J, Dijkmans BA, van Soesbergen RM. Destructive joint disease in alpha-mannosidosis. A case report and review of the literature. Clin Rheumatol. 2004;23:40–42. doi: 10.1007/s10067-003-0770-x.
    1. Hale SS, Bales JG, Rosenzweig S, Daroca P, Bennett JT. Bilateral patellar dislocation associated with alpha-mannosidase deficiency. J Pediatr Orthop B. 2006;15:215–219.
    1. Ara JR, Mayayo E, Marzo ME, Guelbenzu S, Chabás A, Pina MA, Calderón C. Neurological impairment in alpha-mannosidosis: a longitudinal clinical and MRI study of a brother and sister. Childs Nerv Syst. 1999;15:369–371. doi: 10.1007/s003810050416.
    1. Ahmmed AU, O'Halloran SM, Roland NJ, Starkey M, Wraith JE. Hearing loss due to mannosidosis and otitis media with effusion. A case report and review of audiological assessments in children with otitis media with effusion. J Laryngol Otol. 2003;117:307–309.
    1. Arbisser AI, Murphree AL, Garcia CA, Howell RR. Ocular findings in mannosidosis. Am J Ophthalmol. 1976;82:465–471.
    1. Kjellman B, Gamstorp I, Brun A, Ockerman PA, Palmgren B. Mannosidosis: a clinical and histopathologic study. J Pediatr. 1969;75:366–373. doi: 10.1016/S0022-3476(69)80260-X.
    1. Yunis JJ, Lewandowski RC, Jr, Sanfilippo SJ, Tsai MY, Foni I, Bruhl HH. Clinical manifestations of mannosidosis – a longitudinal study. Am J Med. 1976;61:841–848. doi: 10.1016/0002-9343(76)90408-3.
    1. Noll RB, Netzloff ML, Kulkarni R. Long-term follow-up of biochemical and cognitive functioning in patients with mannosidosis. Arch Neurol. 1989;46:507–509.
    1. Gordon BA, Carson R, Haust MD. Unusual clinical and ultrastructural features in a boy with biochemically typical mannosidosis. Acta Paediatr Scand. 1980;69:787–792. doi: 10.1111/j.1651-2227.1980.tb07154.x.
    1. Mitchell ML, Erickson RP, Schmid D, Hieber V, Poznanski AK, Hicks SP. Mannosidosis: two brothers with different degrees of disease severity. Clin Genet. 1981;20:191–202.
    1. Michelakakis H, Dimitriou E, Mylona-Karayanni C, Bartsocas CS. Phenotypic variability of mannosidosis type II: report of two Greek siblings. Genet Couns. 1992;3:195–199.
    1. Dietemann JL, Filippi de la Palavesa MM, Tranchant C, Kastler B. MR findings in mannosidosis. Neuroradiology. 1990;32:485–487. doi: 10.1007/BF02426460.
    1. Malm D, Pantel J, Linaker OM. Psychiatric symptoms in alpha-mannosidosis. J Intellect Disabil Res. 2005;49:865–871. doi: 10.1111/j.1365-2788.2005.00765.x.
    1. Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. J Inherit Metab Dis. 2007:631–641. doi: 10.1007/s10545-007-0661-4.
    1. Malm D, Halvorsen DS, Tranebjaerg L, Sjursen H. Immunodeficiency in alpha-mannosidosis: a matched case-control study on immunoglobulins, complement factors, receptor density, phagocytosis and intracellular killing in leucocytes. Eur J Pediatr. 2000;159:699–703. doi: 10.1007/s004310000545.
    1. Michalski JC, Klein A. Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta. 1999;1455:69–84.
    1. Zanetta JP, Bonaly R, Maschke S, Strecker G, Michalski JC. Differential binding of lectins IL-2 and CSL to candida albicans and cancer cells. Glycobiology. 1998;8:221–225. doi: 10.1093/glycob/8.3.221.
    1. Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity. 2007;27:308–320. doi: 10.1016/j.immuni.2007.06.008.
    1. Segoloni GP, Colla L, Messina M, Stratta P. Renal transplantation in a case of mannosidosis. Transplantation. 1996;61:1654–1655. doi: 10.1097/00007890-199606150-00019.
    1. Roces DP, Lüllmann-Rauch R, Peng J, Balducci C, Andersson C, Tollersrud O, Fogh J, Orlacchio A, Beccari T, Saftig P, von Figura K. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum Mol Genet. 2004;13:1979–1988. doi: 10.1093/hmg/ddh220.
    1. Michalski JC, Haeuw JF, Wieruszeski JM, Montreuil J, Strecker G. In vitro hydrolysis of oligomannosyl oligosaccharides by the lysosomal alpha-D-mannosidases. Eur J Biochem. 1990;189:369–379. doi: 10.1111/j.1432-1033.1990.tb15498.x.
    1. Daniel PF, Winchester B, Warren CD. Mammalian alpha-mannosidases – multiple forms but a common purpose? Glycobiology. 1994;4:551–566. doi: 10.1093/glycob/4.5.551.
    1. DeGasperi R, al Daher S, Daniel PF, Winchester BG, Jeanloz RW, Warren CD. The substrate specificity of bovine and feline lysosomal alpha-D-mannosidases in relation to alpha-mannosidosis. J Biol Chem. 1991;266:16556–16563.
    1. Yamashita K, Tachibana Y, Mihara K, Okada S, Yabuuchi H, Kobata A. Urinary oligosaccharides of mannosidosis. J Biol Chem. 1980;255:5126–5133.
    1. Thomas GH. Disorders of Glycoprotein Degradation: Alpha-Mannosidosis, beta-Mannosidosis, Fucosidosis, and Sialidosis. In: Schriver CR, Beudet AL, Sly WS, editor. The Metabolic & Molecular Basis of Inherited Diseases. 8. III. New York: McGraw-Hill; 2001. pp. 3507–3516.
    1. Riise HM, Berg T, Nilssen O, Romeo G, Tollersrud OK, Ceccherini I. Genomic structure of the human lysosomal alpha-mannosidase gene (MANB) Genomics. 1997;42:200–207. doi: 10.1006/geno.1997.4668.
    1. Wakamatsu N, Gotoda Y, Saito S, Kawai H. Characterization of the human MANB gene encoding lysosomal alpha-D-mannosidase. Gene. 1997;198:351–357. doi: 10.1016/S0378-1119(97)00337-5.
    1. Liao YF, Lal A, Moremen KW. Cloning, expression, purification, and characterization of the human broad specificity lysosomal acid alpha-mannosidase. J Biol Chem. 1996;271:28348–28358. doi: 10.1074/jbc.271.20.11838.
    1. Nilssen O, Berg T, Riise HM, Ramachandran U, Evjen G, Hansen GM, Malm D, Tranebjaerg L, Tollersrud OK. alpha-Mannosidosis: functional cloning of the lysosomal alpha-mannosidase cDNA and identification of a mutation in two affected siblings. Hum Mol Genet. 1997;6:717–726. doi: 10.1093/hmg/6.5.717.
    1. Gotoda Y, Wakamatsu N, Kawai H, Nishida Y, Matsumoto T. Missense and nonsense mutations in the lysosomal alpha-mannosidase gene (MANB) in severe and mild forms of alpha-mannosidosis. Am J Hum Genet. 1998;63:1015–1024. doi: 10.1086/302048.
    1. Frostad Riise HM, Hansen GM, Tollersrud OK, Nilssen O. Characterization of a novel alpha-mannosidosis-causing mutation and its use in leukocyte genotyping after bone marrow transplantation. Hum Genet. 1999;104:106–107. doi: 10.1007/s004390050918.
    1. Beccari T, Bibi L, Ricci R, Antuzzi D, Burgalossi A, Costanzi E, Orlacchio A. Two novel mutations in the gene for human alpha-mannosidase that cause alpha-mannosidosis. J Inherit Metab Dis. 2003;26:819–820. doi: 10.1023/B:BOLI.0000010006.87571.48.
    1. Sbaragli M, Bibi L, Pittis MG, Balducci C, Heikinheimo P, Ricci R, Antuzzi D, Parini R, Spaccini L, Bembi B, Beccari T. Identification and characterization of five novel MAN2B1 mutations in Italian patients with alpha-mannosidosis. Hum Mutat. 2005;25:320. doi: 10.1002/humu.9310.
    1. Pittis MG, Montalvo AL, Heikinheimo P, Sbaragli M, Balducci C, Persichetti E, Van Maldergem L, Filocamo M, Bembi B, Beccari T. Funtional characterization of four novel MAN2B1 mutations causing juvenile onset alpha-mannosidosis. Clin Chim Acta. 2007;375:136–139. doi: 10.1016/j.cca.2006.06.034.
    1. Lyons MJ, Wood T, Espinoza L, Stensland HM, Holden KR. Early onset alpha-mannosidosis with slow progression in three Hispanic males. Dev Med Child Neurol. 2007;49:854–857.
    1. Hansen G, Berg T, Riise Stensland HM, Heikinheimo P, Klenow H, Evjen G, Nilssen Ø, Tollersrud OK. Intracellular transport of human lysosomal alpha-mannosidase and alpha-mannosidosis-related mutants. Biochem J. 2004;381:537–546. doi: 10.1042/BJ20031499.
    1. Warner TG, Mock AK, Nyhan WL, O'Brien JS. Alpha-mannosidosis: analysis of urinary oligosaccharides with high performance liquid chromatography and diagnosis of a case with unusually mild presentation. Clin Genet. 1984;25:248–255.
    1. Abraham D, Muir H, Winchester B, Olsen I. Lymphocytes transfer only the lysosomal form of alpha-D-mannosidase during cell-to-cell contact. Exp Cell Res. 1988;175:158–168. doi: 10.1016/0014-4827(88)90263-7.
    1. Grard T, Herman V, Saint-Pol A, Kmiecik D, Labiau O, Mir AM, Alonso C, Verbert A, Cacan R, Michalski JC. Oligomannosides or oligosaccharide-lipids as potential substrates for rat liver cytosolic alpha-D-mannosidase. Biochem J. 1996;316:787–792.
    1. Egge H, Michalski JC, Strecker G. Heterogeneity of urinary oligosaccharides from mannosidosis: mass spectrometric analysis of permethylated Man9, Man8, and Man7 derivatives. Arch Biochem Biophys. 1982;213:318–326. doi: 10.1016/0003-9861(82)90468-4.
    1. Olsen I, Abraham D, Shelton I, Bou-Gharios G, Muir H, Winchester B. Cell contact induces the synthesis of a lysosomal enzyme precursor in lymphocytes and its direct transfer to fibroblasts. Biochim Biophys Acta. 1988;968:312–322. doi: 10.1016/0167-4889(88)90022-5.
    1. Will A, Cooper A, Hatton C, Sardharwalla IB, Evans DI, Stevens RF. Bone marrow transplantation in the treatment of alpha-mannosidosis. Arch Dis Child. 1987;62:1044–1049.
    1. Walkley SU, Thrall MA, Dobrenis K, Huang M, March PA, Siegel DA, Wurzelmann S. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc Natl Acad Sci USA. 1994;91:2970–2974. doi: 10.1073/pnas.91.8.2970.
    1. Grewal SS, Shapiro EG, Krivit W, Charnas L, Lockman LA, Delaney KA, Davies SM, Wenger DA, Rimell FL, Abel S, Grovas AC, Orchard PJ, Wagner JE, Peters C. Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. J Pediatr. 2004;144:569–573. doi: 10.1016/j.jpeds.2004.01.025.
    1. Wall DA, Grange DK, Goulding P, Daines M, Luisiri A, Kotagal S. Bone marrow transplantation for the treatment of alpha-mannosidosis. J Pediatr. 1998;133:282–285. doi: 10.1016/S0022-3476(98)70237-9.
    1. Crawley AC, King B, Berg T, Meikle PJ, Hopwood JJ. Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. Mol Genet Metab. 2006;89:48–57. doi: 10.1016/j.ymgme.2006.05.005.
    1. DeLano WL. The PyMOL Molecular Graphics System. DeLano Scientific, Palo Alto, CA, USA; 2002.

Source: PubMed

3
Abonneren